Drug–drug interactions of a two-drug regimen of dolutegravir and lamivudine for HIV treatment

References

• Rossetti B, Montagnani F, De Luca A. Current and emerging two-drug approaches for HIV-1 therapy in ART-naïve and ART-experienced, virologically suppressed patients. Expert Opin Pharmacother. 2018;19:713–738.
   Google Scholar
• Soriano V, Fernandez-Montero JV, Benitez-Gutierrez L, et al. Dual antiretroviral therapy for HIV infection. Expert Opin Drug Saf. 2017;16:923–932.
   Google Scholar
• Calza L, Manfredi R. Protease inhibitor monotherapy as maintenance regimen in patients with HIV infection. Curr HIV Res. 2012 Dec;10(8):661–672.
   Google Scholar
• Mathis S, Khanlari B, Pulido F, et al. Effectiveness of protease inhibitor monotherapy versus combination antiretroviral maintenance therapy: a meta-analysis. PLoS One. 2011;6:e22003.
   Google Scholar
• Capetti AF, Cossu MV, Paladini L, et al. Dolutegravir plus rilpivirine dual therapy in treating HIV-1 infection. Expert Opin Pharmacother. 2018;19:65–77.
   Google Scholar
• Capetti AF, Astuti N, Cattaneo D, et al. Pharmacokinetic drug evaluation of dolutegravir plus rilpivirine for the treatment of HIV. Expert Opin Drug Metab Toxicol. 2017;13:1183–1192.
   Google Scholar
• Cahn P, Sierra Madero J, Arribas SR, et al. Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials. Lancet. 2018. [ e-pub ahead of print]. DOI:10.1016/S0140-6736(18)32462-0.
   Google Scholar
• Joly V, Burdet C, Landman R, et al. Dolutegravir and lamivudine maintenance therapy in HIV-1 virologically suppressed patients: results of the ANRS 167 trial (LAMIDOL). J Antimicrob Chemother. 2018. [ Epub ahead of print].
   Google Scholar
• Borghetti A, Lombardi F, Gagliardini R, et al. Efficacy and tolerability of lamivudine plus dolutegravir compared with lamivudine plus boosted PIs in HIV-1 positive individuals with virologic suppression: a retrospective study from the clinical practice. BMC Infect Dis. 2019;19:59.
   Google Scholar
• Podany AT, Scarsi KK, Fletcher CV. Comparative clinical pharmacokinetics and pharmacodynamics of HIV-1 integrase strand transfer inhibitors. Clin Pharmacokinet. 2017;56:25–40.
   Google Scholar
• Bollen P, Reiss P, Schapiro J, et al. Clinical pharmacokinetics and pharmacodynamics of dolutegravir used as a single tablet regimen for the treatment of HIV-1 infection. Expert Opin Drug Saf. 2015;14:1457–1472.
   Google Scholar
• Letendre SL, Mills AM, Tashima KT, et al. ING116070: a study of the pharmacokinetics and antiviral activity of dolutegravir in cerebrospinal fluid in HIV-1-infected, antiretroviral therapy-naive subjects. Clin Infect Dis. 2014;59:1032–1037.
   Google Scholar
• Sculier D, Doco-Lecompte T, Yerly S, et al. Stable HIV-1 reservoirs on dolutegravir maintenance monotherapy: the MONODO study. HIV Med. 2018 Jun 22. [ Epub ahead of print]. DOI:10.1111/hiv.12626
   Google Scholar
• Tivicay Product Monograph - ViiV Healthcare Canada. [cited 2018 Dec 12]. Available from: https://www.viivhealthcare.ca/media/151925/tivicay.pdf
   Google Scholar
• Cattaneo D, Minisci D, Cozzi V, et al. Dolutegravir plasma concentrations according to companion antiretroviral drug: unwanted drug interaction or desirable boosting effect? Antivir Ther. 2017;22:353–356.
   Google Scholar
• Marzolini C, Gibbons S, Khoo S, et al. Cobicistat versus ritonavir boosting and differences in the drug-drug interaction profiles with co-medications. J Antimicrob Chemother. 2016;71:1755–1758.
   Google Scholar
• Gervasoni C, Riva A, Cozzi V, et al. Effects of ritonavir and cobicistat on dolutegravir exposure: when the booster can make the difference. J Antimicrob Chemother. 2017;72:1842–1844.
   Google Scholar
• Reese MJ, Savina PM, Generaux GT, et al. In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor. Drug Metab Dispos. 2013;41:353–361.
   Google Scholar
• Müller F, Fromm MF. Transporter-mediated drug-drug interactions. Pharmacogenomics. 2011;12:1017–1037.
   Google Scholar
• Dooley KE, Sayre P, Borland J, et al. Safety, tolerability, and pharmacokinetics of the HIV integrase inhibitor dolutegravir given twice daily with rifampin or once daily with rifabutin: results of a phase 1 study among healthy subjects. J Acquir Immune Defic Syndr. 2013;62:21–27.
   Google Scholar
• Song I, Weller S, Patel J, et al. Effect of carbamazepine on dolutegravir pharmacokinetics and dosing recommendation. Eur J Clin Pharmacol. 2016;72:665–670.
   Google Scholar
• Kandil MM, Badowski ME, Schriever CA. Sustained viral suppression with co-administration of oxcarbazepine and dolutegravir. Int J STD AIDS. 2018;29:831–833.
   Google Scholar
• Song I, Borland J, Arya N, et al. Pharmacokinetics of dolutegravir when administered with mineral supplements in healthy adult subjects. J Clin Pharmacol. 2015;55:490–496.
   Google Scholar
• MacBrayne CE, Castillo-Mancilla J, Burton JR Jr., et al. Small increase in dolutegravir trough, but equivalent total dolutegravir exposure with simeprevir in HIV/HCV seronegative volunteers. J Antimicrob Chemother. 2018;73:156–159.
   Google Scholar
• Khatri A, Trinh R, Zhao W, et al. Drug-drug interaction between the direct-acting antiviral regimen of ombitasvir-paritaprevir-ritonavir plus dasabuvir and the HIV antiretroviral agent dolutegravir or abacavir plus lamivudine. Antimicrob Agents Chemother. 2016;60:6244–6251.
   Google Scholar
• Walimbwa SI, Lamorde M, Waitt C, et al. Drug interactions between dolutegravir and artemether-lumefantrine or artesunate-amodiaquine. Antimicrob Agents Chemother. 2018. [ Epub ahead of print].
   Google Scholar
• Palazzo A, Trunfio M, Pirriatore V, et al. Lower dolutegravir plasma concentrations in HIV-positive patients receiving valproic acid. J Antimicrob Chemother. 2017 Dec 12. [ Epub ahead of print]. DOI:10.1093/jac/dkx461
   Google Scholar
• Song IH, Zong J, Borland J, et al. The effect of dolutegravir on the pharmacokinetics of metformin in healthy subjects. J Acquir Immune Defic Syndr. 2016;72:400–407.
   Google Scholar
• Gervasoni C, Minisci D, Clementi E, et al. How relevant is the interaction between dolutegravir and metformin in real life? J Acquir Immune Defic Syndr. 2017;75:e24–e26.
   Google Scholar
• Kajbaf F, De Broe ME, Lalau JD. Therapeutic concentrations of metformin: A systematic review. Clin Pharmacokinet. 2016;55:439–459.
   Google Scholar
• Cattaneo D, Resnati C, Rizzardini G, et al. Dolutegravir and metformin: a clinically relevant or just a pharmacokinetic interaction? AIDS. 2018;32:532–533.
   Google Scholar
• Naccarato M, Yoong D, Fong IW. Dolutegravir and metformin: a case of hyperlactatemia. Aids. 2017;31:2176–2177.
   Google Scholar
• Brooks KM, George JM, Pau AK, et al. Cytokine-mediated systemic adverse drug reactions in a drug-drug interaction study of dolutegravir with once-weekly isoniazid and rifapentine. Clin Infect Dis. 2018;67:193–201.
   Google Scholar
• Johnson MA, Moore KH, Yuen GJ, et al. Clinical pharmacokinetics of lamivudine. Clin Pharmacokinet. 1999;36:41–66.
   Google Scholar
• Kumar PN, Patel P. Lamivudine for the treatment of HIV. Expert Opin Drug Metab Toxicol. 2010;6:105–114.
   Google Scholar
• Cattaneo D, Gervasoni C. Novel antiretroviral drugs in patients with renal impairment: clinical and pharmacokinetic considerations. Eur J Drug Metab Pharmacokinet. 2017;42:559–572.
   Google Scholar
• Ceckova M, Reznicek J, Deutsch B, et al. Efavirenz reduces renal excretion of lamivudine in rats by inhibiting organic cation transporters (OCT, Oct) and multidrug and toxin extrusion proteins (MATE, Mate). PLoS One. 2018;13:e0202706.
   Google Scholar
• Li Q, Ye Z, Zhu P, et al. Indinavir alters the pharmacokinetics of lamivudine partially via inhibition of multidrug and toxin extrusion protein 1 (MATE1). Pharm Res. 2018;35:14.
   Google Scholar
• Müller F, König J, Hoier E, et al. Role of organic cation transporter OCT2 and multidrug and toxin extrusion proteins MATE1 and MATE2-K for transport and drug interactions of the antiviral lamivudine. Biochem Pharmacol. 2013;86:808–815.
   Google Scholar
• Nakatani-Freshwater T, Babayeva M, Dontabhaktuni A, et al. Effects of trimethoprim on the clearance of apricitabine, a deoxycytidine analog reverse transcriptase inhibitor, and Lamivudine in the isolated perfused rat kidney. J Pharmacol Exp Ther. 2006;319:941–947.
   Google Scholar
• Takubo T, Kato T, Kinami J, et al. Effect of trimethoprim on the renal clearance of lamivudine in rats. J Pharm Pharmacol. 2000;52:315–320.
   Google Scholar
• Lamivudine drug monograph. [cited 2018 Dec 12]. Available from: https://pdf.hres.ca/dpd_pm/00041729.PDF
   Google Scholar
• Adkison K, Wolstenholme A, Lou Y, et al. Effect of sorbitol on the pharmacokinetic profile of lamivudine oral solution in adults: an open-label, randomized study. Clin Pharmacol Ther. 2018;103:402–408.
   Google Scholar
• Choi SY, Viswanathan P, Sherwat A, et al. Effects of sorbitol on the pharmacokinetics of lamivudine solution and the FDA’s decision to increase the dose of lamivudine solution for pediatric patients. Clin Pharmacol Ther. 2018;104:785–787.
   Google Scholar
• Bakare-Odunola MT, Enemali I, Garba M, et al. The influence of lamivudine, stavudine and nevirapine on the pharmacokinetics of chlorpropamide in human subjects. Eur J Drug Metab Pharmacokinet. 2008;33:165–171.
   Google Scholar
• McGettrick P, Barco EA, Mallon PWG. Ageing with HIV. Healthcare (Basel). 2018;6:E17.
   Google Scholar
• Negredo E, Back D, Blanco JR, et al. Aging in HIV-infected subjects: a new scenario and a new view. Biomed Res Int. 2017;2017:5897298.
   Google Scholar
• Kaplan-Lewis E, Aberg JA, Lee M. Aging with HIV in the ART era. Semin Diagn Pathol. 2017;34:384–397.
   Google Scholar
• Guaraldi G, Palella FJ Jr. Clinical implications of aging with HIV infection: perspectives and the future medical care agenda. AIDS. 2017;31(Suppl 2):S129–S135.
   Google Scholar
• Smith JM, Flexner C. The challenge of polypharmacy in an aging population and implications for future antiretroviral therapy development. Aids. 2017;31(Suppl 2):S173–S184.
   Google Scholar
• Alberts LH. Polypharmacy, using new treatments to customize care for aging patients and adherence present and future. Interdiscip Top Gerontol Geriatr. 2017;42:74–84.
   Google Scholar
• Pasina L, Djade CD, Nobili A, et al. Drug-drug interactions in a cohort of hospitalized elderly patients. Pharmacoepidemiol Drug Saf. 2013;22:1054–1060.
   Google Scholar
• Scondotto G, Pojero F, Pollina Addario S, et al. The impact of polypharmacy and drug interactions among the elderly population in Western Sicily, Italy. Aging Clin Exp Res. 2018;30:81–87.
   Google Scholar
• Salbu RL, Feuer J. A closer look at the 2015 beers criteria. J Pharm Pract. 2017;30:419–424.
   Google Scholar
• Hill-Taylor B, Walsh KA, Stewart S, et al. Effectiveness of the STOPP/START (Screening Tool of Older Persons’ potentially inappropriate Prescriptions/Screening Tool to Alert doctors to the Right Treatment) criteria: systematic review and meta-analysis of randomized controlled studies. J Clin Pharm Ther. 2016;41:158–169.
   Google Scholar
• Bjerre LM, Ramsay T, Cahir C, et al. Assessing potentially inappropriate prescribing (PIP) and predicting patient outcomes in Ontario’s older population: a population-based cohort study applying subsets of the STOPP/START and Beers’ criteria in large health administrative databases. BMJ Open. 2015;5:e010146.
   Google Scholar
• McNicholl IR, Gandhi M, Hare CB, et al. A Pharmacist-Led Program to Evaluate and Reduce Polypharmacy and Potentially Inappropriate Prescribing in Older HIV-Positive Patients. Pharmacotherapy. 2017;37:1498–1506.
   Google Scholar